Cencora (NYSE:COR – Get Free Report) and LifeStance Health Group (NASDAQ:LFST – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.
Profitability
This table compares Cencora and LifeStance Health Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cencora | 1.03% | 110.72% | 4.22% |
| LifeStance Health Group | 4.29% | 4.82% | 3.30% |
Analyst Ratings
This is a breakdown of current recommendations for Cencora and LifeStance Health Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cencora | 0 | 3 | 13 | 0 | 2.81 |
| LifeStance Health Group | 0 | 4 | 5 | 1 | 2.70 |
Cencora presently has a consensus target price of $381.00, indicating a potential upside of 11.64%. LifeStance Health Group has a consensus target price of $14.86, indicating a potential upside of 12.34%. Given LifeStance Health Group’s higher probable upside, analysts clearly believe LifeStance Health Group is more favorable than Cencora.
Volatility & Risk
Cencora has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Insider and Institutional Ownership
97.5% of Cencora shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 0.4% of Cencora shares are held by company insiders. Comparatively, 3.5% of LifeStance Health Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cencora and LifeStance Health Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cencora | $638.56 million | 101.99 | $3.48 billion | $17.92 | 19.04 |
| LifeStance Health Group | $1.68 billion | 3.00 | $9.66 million | $0.19 | 69.61 |
Cencora has higher earnings, but lower revenue than LifeStance Health Group. Cencora is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.
Summary
Cencora beats LifeStance Health Group on 8 of the 15 factors compared between the two stocks.
About Cencora
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
About LifeStance Health Group
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
